Abstract：Objective To investigate the effect of Shexiang Baoxin Pills combined with Low Molecular Weight Heparin Calcium in the treatment of acute ST-segment elevation myocardial infarction (STEMI). Methods A total of 90 STEMI patients who admitted to Anhui No.2 Provincial People′s Hospital from January 2017 to July 2019 were selected, they were divided into the control group (45 cases) and the study group (45 cases) according to the random number table method. The control group was treated with Low Molecular Weight Heparin Calcium. The study group was treated with Shexiang Baoxin Pills on the basis of the control group. The clinical efficacy, cardiac function and serological indexes of the two groups were compared, the adverse reactions and the occurrence of early adverse cardiac events during the treatment were recorded. Results After two courses of treatment, the total effective rate of the study group was significantly higher than that of the control group (P ＜ 0.05). After 2 courses of treatment, left ventricular ejection fraction and nitric oxide increased in the two groups were increased, and the study group was higher than the control group (P ＜ 0.05). After 2 courses of treatment, the diameters of left ventricular end systolic period, left ventricular end diastolic period, endothelin and hypersensitive c-reactive protein of the two groups were decreased, and the study group was lower than those in the control group (P ＜ 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P ＞ 0.05). However, the total incidence of adverse cardiac events in the study group was lower than that in the control group (P ＜ 0.05). Conclusion Shexiang Baoxin Pills combines with Low Molecular Weight Heparin Calcium is effective in treating STEMI, which can effectively improve cardiac function and vascular endothelial function, alleviate inflammatory reaction of the body, and has good safety, which can reduce the total incidence of adverse cardiac events, and has a high clinical application value.
2020, Vol. 17 
京公网安备 11010502046598号